ALK and lung adenocarcinoma: Similarly, National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) recommend all patients with lung adenocarcinoma to be tested for ALK rearrangements, among other genetic alterations [11,12].